Latest Benzimidazoles Stories
RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LYÂ® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan.
Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed.
The recent approval of a drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm.
RIDGEFIELD, Conn., Nov. 1, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- The U.S.
DEXILANT is the First Proton Pump Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology MISSISSAUGA, ON, Sept.
RIDGEFIELD, Conn., Aug. 29 /PRNewswire/ -- Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LYÂ® trial - the largest atrial fibrillation outcomes trial ever conducted(2) - were published in The Lancet.
PARIS, July 27 /PRNewswire-FirstCall/ -- Medco Research Institute(TM), LLC, a wholly owned subsidiary of Medco Health Solutions, Inc.
CINCINNATI, July 1 /PRNewswire/ -- Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERIDÂ® (omeprazole/sodium bicarbonate) capsules.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.